CareDx, Inc. (NASDAQ:CDNA) Director Peter Maag Sells 10,000 Shares

CareDx, Inc. (NASDAQ:CDNA - Get Free Report) Director Peter Maag sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $19.24, for a total value of $192,400.00. Following the completion of the sale, the director now owns 318,846 shares in the company, valued at $6,134,597.04. This represents a 3.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Peter Maag also recently made the following trade(s):

• On Wednesday, April 30th, Peter Maag sold 13,281 shares of CareDx stock. The stock was sold at an average price of $17.23, for a total value of $228,831.63.

CareDx Price Performance

NASDAQ:CDNA traded up $0.01 during trading hours on Friday, reaching $19.04. 1,719,282 shares of the company were exchanged, compared to its average volume of 921,719. The company has a market capitalization of $1.06 billion, a P/E ratio of 16.56 and a beta of 2.18. CareDx, Inc. has a 1-year low of $13.74 and a 1-year high of $34.84. The business has a 50 day moving average of $17.57 and a 200 day moving average of $20.07.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. The firm had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. CareDx had a return on equity of 21.16% and a net margin of 19.79%. The company's revenue was up 17.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.03) EPS. As a group, equities research analysts anticipate that CareDx, Inc. will post -0.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CareDx

A number of large investors have recently modified their holdings of CDNA. Allspring Global Investments Holdings LLC boosted its holdings in shares of CareDx by 59.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 327,343 shares of the company's stock valued at $7,008,000 after purchasing an additional 122,356 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of CareDx by 1.8% in the 4th quarter. Rhumbline Advisers now owns 81,201 shares of the company's stock valued at $1,738,000 after purchasing an additional 1,451 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of CareDx by 6.5% in the 4th quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock valued at $406,000 after purchasing an additional 1,151 shares in the last quarter. Ieq Capital LLC acquired a new stake in shares of CareDx in the 4th quarter valued at $970,000. Finally, Thompson Davis & CO. Inc. boosted its holdings in shares of CareDx by 6.3% in the 4th quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company's stock valued at $344,000 after purchasing an additional 950 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Wall Street Zen lowered CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. HC Wainwright reiterated a "neutral" rating and set a $25.00 target price on shares of CareDx in a research note on Monday, May 5th. The Goldman Sachs Group lowered their target price on CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Finally, Stephens reissued an "overweight" rating and set a $40.00 price target on shares of CareDx in a research report on Monday, May 5th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, CareDx has an average rating of "Moderate Buy" and an average price target of $30.33.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.